Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)

v3.26.1
Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Mar. 31, 2021
USD ($)
item
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs     $ 8,000  
Long-term royalty and commercial payment receivables under the cost recovery method   $ 55,886   $ 55,888
Trade and other receivables, net   4,595   4,896
Income from purchased receivables under cost recovery method   2,769 5,525  
Income from purchased receivables under cost recovery method, Milestones     4,000  
Income from purchased receivables under cost recovery method, Royalties     1,500  
Viracta | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 2      
Payments of consideration under RPAs, AAAs and CPPAs $ 13,500      
Maximum amount of potential milestones, potential royalties on sales and other payments receivable 54,000      
Amount of maximum consideration retained 5,000      
Maximum amount of potential regulatory and commercial milestones receivable $ 57,000      
Trade and other receivables, net   2,800   $ 2,600
Income from purchased receivables under cost recovery method   $ 2,800 $ 5,500